ファーマコビジランスの世界市場

ファーマコビジランスの世界市場は2030年までに185億米ドルに達する見込み

2023年に100億米ドルと推定されるファーマコビジランスの世界市場は、2023年から2030年にかけてCAGR 9.2%で成長し、2030年には185億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである契約型アウトソーシングは、CAGR 11.1%を記録し、分析期間終了時には123億米ドルに達すると予測されます。インハウスサービスプロバイダーセグメントの成長率は、分析期間中CAGR 6.1%と推定されます。

米国市場は26億米ドル、中国はCAGR12.7%で成長すると予測

米国のファーマコビジランス市場は2023年に26億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに43億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは12.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ5.7%と7.5%と予測されています。欧州では、ドイツがCAGR約6.9%で成長すると予測されています。

世界のファーマコビジランス市場- 主要動向と促進要因まとめ

ファーマコビジランスとは何か、なぜヘルスケアで重要なのか？

ファーマコビジランスとは、副作用やその他の薬物関連問題の検出、評価、理解、予防に関連する科学と活動を指します。開発から市販後調査に至るまで、医薬品のライフサイクル全体を通じて安全性と有効性を確保する上で重要な役割を担っています。ファーマコビジランスの主な目的は、医薬品の使用に関連するリスクを特定し、軽減することによって公衆衛生を守ることです。医薬品には、臨床試験中には十分に明らかにならない副作用があるため、ファーマコビジランスは、医薬品が広く使用されるようになってからも、その安全性を継続的に監視する仕組みを提供します。

ファーマコビジランスは、副作用報告（ADR）のデータ収集・分析、リスクアセスメントの実施、患者への危害を軽減するための対策の実施など、様々な活動を包含しています。規制当局、製薬会社、ヘルスケア専門家のすべてがファーマコビジランスに関与し、医薬品に関する潜在的な安全性の懸念が迅速に特定され、対処されることを保証します。製薬業界が生物製剤や個別化治療薬など、より複雑な新薬を開発し続ける中、ファーマコビジランスは医薬品の安全性を維持し、患者を保護する上で、さらに重要なものとなっています。

技術の進歩はどのようにファーマコビジランス市場を形成していますか？

技術の進歩は、ファーマコビジランス市場において変革的な役割を果たしており、医薬品安全性監視の効率と精度を向上させ、潜在的なリスクを特定する能力を高めています。この分野における最も重要な進歩の一つは、人工知能（AI）と機械学習（ML）をファーマコビジランスプロセスに統合することです。AIやMLのアルゴリズムは、患者記録、ソーシャルメディア上の発言、電子カルテなどの大量の実世界データを分析し、副作用（ADR）を示す可能性のあるパターンを特定することができます。これらの技術は、より積極的なモニタリングを可能にし、潜在的な安全性の懸念が広まる前に早期発見することを可能にします。

自動化は、ファーマコビジランス市場を形成するもう一つの重要な動向です。自動化されたシステムは、データ収集、レポート作成、信号検出などのタスクを、従来の手作業よりも高速かつ正確に処理することができます。例えば、ロボティック・プロセス・オートメーション（RPA）は、ADRレポートの収集と分析を合理化し、応答時間を改善し、人的ミスを減らすために使用されています。さらに、自然言語処理（NLP）技術により、臨床記録や患者報告書などの非構造化データソースから関連する安全性情報を抽出する能力が強化され、他の方法では気づかれない可能性のある副作用の特定が容易になっています。

さらに、クラウドベースのファーマコビジランスプラットフォームの台頭により、製薬会社、規制当局、ヘルスケアプロバイダーなどの利害関係者間のコラボレーションが活発化しています。これらのプラットフォームは、ADRデータをリアルタイムで保存、共有、分析できる集中型データベースを提供し、より迅速な意思決定と効率的な報告を可能にしています。さらに、ビッグデータ解析の採用により、企業は膨大な量の患者データを分析して、潜在的な安全性の問題を示す可能性のある傾向や相関関係を特定できるようになり、市販後調査に革命をもたらしています。

ファーマコビジランスの新たな動向とは？

製薬業界が進化する課題と機会に直面する中、いくつかの新たな動向がファーマコビジランス市場を再構築しています。最も重要な動向の一つは、医薬品安全性モニタリングにおけるリアルワールドエビデンス（RWE）への注目の高まりです。RWEは、患者記録、保険請求、登録など、臨床試験以外で収集されたデータから得られるもので、実世界の環境において医薬品がどのように作用するかをより幅広く理解することができます。RWEを使用することで、特に多様な患者集団において、管理された臨床環境とは異なる挙動を示す可能性のある医薬品について、より包括的な安全性評価が可能になります。その結果、製薬企業や規制当局は、RWEを自社のファーマコビジランス戦略に取り入れるようになってきています。

もう一つの重要な動向は、ファーマコビジランスの世界化の進展です。製薬企業が国際市場に進出するにつれ、各地域の多様な規制要件に対応する必要があります。そのため、安全性データが現地の規制を遵守して収集され、報告されることを保証しながら、世界に運用できるファーマコビジランスサービスへの需要が高まっています。米国、欧州、アジア太平洋などの規制当局は、医薬品の安全性に関する厳格なガイドラインを策定しており、製薬会社はこれらの基準を満たすことができる強固なファーマコビジランスシステムを維持する必要があります。

ファーマコビジランスにおいても、リスクマネジメントとプロアクティブな安全性モニタリングが重要性を増しています。有害事象が発生してから対応するのではなく、潜在的な安全性問題が発生する前に予防するために、リスク管理計画（RMP）やリスク軽減戦略を採用する企業が増えています。これらのアプローチには、市販前のリスク評価、市販後の継続的な監視、データ動向から新たなリスクを特定するシグナル検出ツールの使用などが含まれます。さらに、患者中心のファーマコビジランスの台頭は、患者からの直接的なインプットの重要性を強調しており、企業は調査、ソーシャルメディア、モバイルヘルスアプリを活用して、患者が報告する転帰や薬剤の使用経験を収集しています。

何がファーマコビジランス市場の成長を促進しているのか？

ファーマコビジランス市場の成長は、規制当局による監視の強化、薬物療法の複雑化、技術革新など、いくつかの要因によってもたらされます。特に、生物製剤、遺伝子治療、個別化医療などの分野では、新薬の承認数が増加していることが主な要因の1つです。これらの治療法は複雑な安全性プロファイルを伴うことが多く、より集中的な市販後モニタリングが必要となります。製薬企業がより革新的で個別化された医薬品を市場に投入するにつれて、患者の安全性を確保するための包括的なファーマコビジランスサービスに対する需要が大幅に増加すると予想されます。

市場成長を促進するもう一つの重要な要因は、医薬品の安全性に関する規制要件の増加です。米国FDAや欧州医薬品庁（EMA）などの規制機関は、ファーマコビジランスに関する厳格なガイドラインを導入しており、企業は医薬品が上市承認を受けた後も継続的なモニタリングを実施することを求めています。これらの規制を遵守しなかった場合、多額の罰則、製品回収、企業の評判の低下を招く可能性があります。そのため、製薬会社はコンプライアンスを確保し、規制リスクを回避するために、ファーマコビジランスシステムに多額の投資を行っています。

技術の進歩もファーマコビジランス市場の成長に寄与しています。AI、自動化、ビッグデータ解析の統合は、企業の医薬品安全性モニタリングへのアプローチ方法に革命をもたらし、より効率的でスケーラブル、かつ費用対効果の高いものとなっています。これらの技術により、企業は膨大な量のデータをリアルタイムで分析できるようになり、安全性評価のスピードと精度が向上しています。さらに、クラウドベースのソリューションと世界なファーマコビジランスネットワークの台頭により、製薬業界全体のコラボレーションとデータ共有が促進され、市場のさらなる成長を後押ししています。

最後に、患者の安全性と透明性への注目の高まりが、主要な促進要因となっています。患者が医薬品に関連する潜在的リスクについてより多くの情報を得るようになるにつれ、製薬会社は医薬品の安全性を確保し、有害事象を迅速かつ透明性をもって報告するよう、より大きなプレッシャーにさらされています。説明責任の強化と患者中心のアプローチへのシフトは、医薬品の安全性を監視し、規制当局やヘルスケアプロバイダーにタイムリーな最新情報を提供できる堅牢なファーマコビジランスシステムに対する需要を促進しています。これらの要因は、革新的な治療法の継続的な開発と相まって、ファーマコビジランス市場の成長を今後も牽引していくと予想されます。

調査対象企業の例（全32件）

• Accenture
• ArisGlobal
• BioClinica Inc.
• Capgemini
• Cognizant
• FMD K&L
• IBM Corporation
• ICON Plc
• IQVIA
• ITClinical
• Laboratory Corporation of America Holdings
• Linical Accelovance
• Parexel International Corporation
• TAKE Solutions Ltd.
• United BioSource Corporation
• Wipro Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Pharmacovigilance Market to Reach US$18.5 Billion by 2030

The global market for Pharmacovigilance estimated at US$10.0 Billion in the year 2023, is expected to reach US$18.5 Billion by 2030, growing at a CAGR of 9.2% over the analysis period 2023-2030. Contract Outsourcing, one of the segments analyzed in the report, is expected to record a 11.1% CAGR and reach US$12.3 Billion by the end of the analysis period. Growth in the In-House Service Provider segment is estimated at 6.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.6 Billion While China is Forecast to Grow at 12.7% CAGR

The Pharmacovigilance market in the U.S. is estimated at US$2.6 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$4.3 Billion by the year 2030 trailing a CAGR of 12.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.7% and 7.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.9% CAGR.

Global Pharmacovigilance Market – Key Trends & Drivers Summarized

What Is Pharmacovigilance and Why Is It Important in Healthcare?

Pharmacovigilance refers to the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or other drug-related problems. It plays a crucial role in ensuring the safety and efficacy of pharmaceutical products throughout their lifecycle, from development to post-market surveillance. The primary goal of pharmacovigilance is to protect public health by identifying and mitigating risks associated with the use of drugs. As pharmaceutical products can have side effects that are not fully apparent during clinical trials, pharmacovigilance provides an ongoing mechanism for monitoring the safety of drugs once they are in widespread use.

Pharmacovigilance encompasses various activities, such as collecting and analyzing data from adverse drug reaction (ADR) reports, conducting risk assessments, and implementing measures to reduce harm to patients. Regulatory authorities, pharmaceutical companies, and healthcare professionals are all involved in pharmacovigilance, ensuring that any potential safety concerns related to a drug are quickly identified and addressed. As the pharmaceutical industry continues to develop new and more complex drugs, including biologics and personalized therapies, pharmacovigilance has become even more critical in maintaining drug safety and protecting patients.

How Are Technological Advancements Shaping the Pharmacovigilance Market?

Technological advancements are playing a transformative role in the pharmacovigilance market, improving the efficiency and accuracy of drug safety monitoring and enhancing the ability to identify potential risks. One of the most significant advancements in this field is the integration of artificial intelligence (AI) and machine learning (ML) into pharmacovigilance processes. AI and ML algorithms are capable of analyzing large volumes of real-world data, such as patient records, social media mentions, and electronic health records, to identify patterns that may indicate adverse drug reactions (ADRs). These technologies allow for more proactive monitoring, enabling early detection of potential safety concerns before they become widespread.

Automation is another key trend shaping the pharmacovigilance market. Automated systems can handle tasks such as data collection, report generation, and signal detection with greater speed and accuracy than traditional manual methods. For instance, robotic process automation (RPA) is being used to streamline the collection and analysis of ADR reports, improving response times and reducing human error. In addition, natural language processing (NLP) technologies are enhancing the ability to extract relevant safety information from unstructured data sources, such as clinical notes and patient reports, making it easier to identify adverse reactions that might otherwise go unnoticed.

Furthermore, the rise of cloud-based pharmacovigilance platforms is enabling greater collaboration between stakeholders, including pharmaceutical companies, regulatory authorities, and healthcare providers. These platforms offer centralized databases where ADR data can be stored, shared, and analyzed in real-time, allowing for faster decision-making and more efficient reporting. Additionally, the adoption of big data analytics is revolutionizing post-market surveillance, as companies can now analyze vast amounts of patient data to identify trends and correlations that could indicate potential safety issues.

What Are the Emerging Trends in Pharmacovigilance?

Several emerging trends are reshaping the pharmacovigilance market as the pharmaceutical industry faces evolving challenges and opportunities. One of the most significant trends is the growing focus on real-world evidence (RWE) in drug safety monitoring. RWE is derived from data collected outside of clinical trials, such as patient records, insurance claims, and registries, providing a broader understanding of how drugs perform in real-world settings. The use of RWE allows for more comprehensive safety assessments, particularly for drugs that may behave differently in diverse patient populations than they do in controlled clinical environments. As a result, pharmaceutical companies and regulators are increasingly incorporating RWE into their pharmacovigilance strategies.

Another key trend is the increased globalization of pharmacovigilance. As pharmaceutical companies expand into international markets, they must comply with the diverse regulatory requirements of different regions. This has led to greater demand for pharmacovigilance services that can operate on a global scale, ensuring that safety data is collected and reported in compliance with local regulations. Regulatory authorities in regions such as the U.S., Europe, and Asia-Pacific have developed stringent guidelines for drug safety, which require pharmaceutical companies to maintain robust pharmacovigilance systems capable of meeting these standards.

Risk management and proactive safety monitoring are also gaining importance in pharmacovigilance. Rather than reacting to adverse events after they occur, companies are increasingly adopting risk management plans (RMPs) and risk mitigation strategies to prevent potential safety issues before they arise. These approaches include pre-market risk assessments, continuous post-market surveillance, and the use of signal detection tools that identify emerging risks from data trends. Additionally, the rise of patient-centric pharmacovigilance emphasizes the importance of direct input from patients, with companies utilizing surveys, social media, and mobile health apps to collect patient-reported outcomes and experiences with medications.

What Is Driving the Growth of the Pharmacovigilance Market?

The growth in the pharmacovigilance market is driven by several factors, including increased regulatory scrutiny, the rising complexity of drug therapies, and technological innovations. One of the primary drivers is the growing number of new drug approvals, particularly in areas such as biologics, gene therapies, and personalized medicines. These therapies are often associated with complex safety profiles, requiring more intensive post-market monitoring. As pharmaceutical companies bring more innovative and personalized drugs to market, the demand for comprehensive pharmacovigilance services to ensure patient safety is expected to rise significantly.

Another important factor driving market growth is the increasing regulatory requirements for drug safety. Regulatory bodies, such as the U.S. FDA and the European Medicines Agency (EMA), have implemented stringent guidelines for pharmacovigilance, requiring companies to conduct ongoing monitoring of drugs even after they receive market approval. Failure to comply with these regulations can result in significant penalties, product recalls, or damage to a company’s reputation. As a result, pharmaceutical companies are investing heavily in pharmacovigilance systems to ensure compliance and avoid regulatory risks.

Technological advancements are also contributing to the growth of the pharmacovigilance market. The integration of AI, automation, and big data analytics has revolutionized the way companies approach drug safety monitoring, making it more efficient, scalable, and cost-effective. These technologies enable companies to analyze vast amounts of data in real-time, improving the speed and accuracy of safety assessments. Furthermore, the rise of cloud-based solutions and global pharmacovigilance networks has facilitated better collaboration and data sharing across the pharmaceutical industry, driving further growth in the market.

Lastly, the increasing focus on patient safety and transparency is a key growth driver. As patients become more informed about the potential risks associated with medications, pharmaceutical companies are under greater pressure to ensure that their drugs are safe and that adverse events are reported quickly and transparently. This shift toward greater accountability and patient-centric approaches is driving the demand for robust pharmacovigilance systems that can monitor drug safety and provide timely updates to regulatory authorities and healthcare providers. These factors, combined with the ongoing development of innovative therapies, are expected to continue driving growth in the pharmacovigilance market in the years to come.

Select Competitors (Total 32 Featured) -

• Accenture
• ArisGlobal
• BioClinica Inc.
• Capgemini
• Cognizant
• FMD K&L
• IBM Corporation
• ICON Plc
• IQVIA
• ITClinical
• Laboratory Corporation of America Holdings
• Linical Accelovance
• Parexel International Corporation
• TAKE Solutions Ltd.
• United BioSource Corporation
• Wipro Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Pharmacovigilance - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Regulatory Scrutiny and Global Safety Standards for Drug Monitoring Drive Growth in Pharmacovigilance Services
  • Rising Incidence of Adverse Drug Reactions (ADRs) and Medication Errors Spurs Demand for Comprehensive Pharmacovigilance Systems
  • Expansion of Biologics, Biosimilars, and Advanced Therapies Strengthens the Role of Pharmacovigilance in Post-Market Surveillance
  • Technological Advancements in Automation, AI, and Machine Learning Enhance Data Analysis and Signal Detection in Pharmacovigilance
  • Growing Adoption of Pharmacovigilance Services in Emerging Markets Expands Global Reach for Drug Safety Monitoring
  • Increasing Collaboration Between Pharmaceutical Companies and Regulatory Authorities for Real-Time Monitoring of Drug Safety
  • Rising Use of Big Data Analytics and Real-World Evidence (RWE) in Pharmacovigilance to Improve Drug Safety Outcomes
  • Expansion of Outsourcing to Contract Research Organizations (CROs) for Pharmacovigilance Services Enhances Efficiency and Compliance
  • Growing Focus on Pharmacovigilance for Personalized Medicine and Gene Therapy Products Drives the Need for Tailored Safety Monitoring
  • Emerging Use of Social Media and Digital Platforms for Pharmacovigilance Data Collection Expands Market for Innovative Safety Solutions
  • Rising Adoption of Cloud-Based Pharmacovigilance Systems for Scalable, Real-Time Drug Safety Monitoring
  • Increased Demand for Pharmacovigilance in the Development and Monitoring of Vaccines, Especially in the Post-Pandemic Era
  • Technological Innovations in Natural Language Processing (NLP) for Automating Pharmacovigilance Case Processing
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Pharmacovigilance by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Pharmacovigilance by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 3: World 16-Year Perspective for Pharmacovigilance by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Contract Outsourcing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Contract Outsourcing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 6: World 16-Year Perspective for Contract Outsourcing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for In-House by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 8: World Historic Review for In-House by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 9: World 16-Year Perspective for In-House by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Cardiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 11: World Historic Review for Cardiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 12: World 16-Year Perspective for Cardiology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Respiratory Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 14: World Historic Review for Respiratory Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 15: World 16-Year Perspective for Respiratory Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 17: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 18: World 16-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 19: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 20: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 21: World 16-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 23: World Historic Review for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 24: World 16-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 25: World Recent Past, Current & Future Analysis for Pharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 26: World Historic Review for Pharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 27: World 16-Year Perspective for Pharma Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 28: World Recent Past, Current & Future Analysis for Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 29: World Historic Review for Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 30: World 16-Year Perspective for Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 31: World Recent Past, Current & Future Analysis for Medical Device Manufacturers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 32: World Historic Review for Medical Device Manufacturers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 33: World 16-Year Perspective for Medical Device Manufacturers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 34: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 35: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 36: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 37: World Recent Past, Current & Future Analysis for Spontaneous Reporting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 38: World Historic Review for Spontaneous Reporting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 39: World 16-Year Perspective for Spontaneous Reporting by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 40: World Recent Past, Current & Future Analysis for Intensified ADR Reporting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 41: World Historic Review for Intensified ADR Reporting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 42: World 16-Year Perspective for Intensified ADR Reporting by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 43: World Recent Past, Current & Future Analysis for Targeted Spontaneous Reporting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 44: World Historic Review for Targeted Spontaneous Reporting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 45: World 16-Year Perspective for Targeted Spontaneous Reporting by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 46: World Recent Past, Current & Future Analysis for Cohort Event Monitoring by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 47: World Historic Review for Cohort Event Monitoring by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 48: World 16-Year Perspective for Cohort Event Monitoring by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 49: World Recent Past, Current & Future Analysis for EHR Mining by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 50: World Historic Review for EHR Mining by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 51: World 16-Year Perspective for EHR Mining by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 52: World Pharmacovigilance Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Pharmacovigilance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 53: USA Recent Past, Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: USA 16-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2014, 2024 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: USA 16-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2014, 2024 & 2030
  • TABLE 59: USA Recent Past, Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: USA 16-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 62: USA Recent Past, Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: USA Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 64: USA 16-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 67: Canada 16-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2014, 2024 & 2030
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 70: Canada 16-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2014, 2024 & 2030
  • TABLE 71: Canada Recent Past, Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Canada Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 73: Canada 16-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 74: Canada Recent Past, Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Canada Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 76: Canada 16-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2014, 2024 & 2030
• JAPAN
  • Pharmacovigilance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 79: Japan 16-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2014, 2024 & 2030
  • TABLE 80: Japan Recent Past, Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 82: Japan 16-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2014, 2024 & 2030
  • TABLE 83: Japan Recent Past, Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Japan Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 85: Japan 16-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 86: Japan Recent Past, Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Japan Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 88: Japan 16-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2014, 2024 & 2030
• CHINA
  • Pharmacovigilance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 89: China Recent Past, Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 90: China Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 91: China 16-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2014, 2024 & 2030
  • TABLE 92: China Recent Past, Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: China Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 94: China 16-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2014, 2024 & 2030
  • TABLE 95: China Recent Past, Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 96: China Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 97: China 16-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 98: China Recent Past, Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 99: China Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 100: China 16-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2014, 2024 & 2030
• EUROPE
  • Pharmacovigilance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Pharmacovigilance by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Pharmacovigilance by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 103: Europe 16-Year Perspective for Pharmacovigilance by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 104: Europe Recent Past, Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 106: Europe 16-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2014, 2024 & 2030
  • TABLE 107: Europe Recent Past, Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Europe Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 109: Europe 16-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2014, 2024 & 2030
  • TABLE 110: Europe Recent Past, Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 111: Europe Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 112: Europe 16-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 113: Europe Recent Past, Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 114: Europe Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 115: Europe 16-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2014, 2024 & 2030
• FRANCE
  • Pharmacovigilance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 116: France Recent Past, Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 117: France Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 118: France 16-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2014, 2024 & 2030
  • TABLE 119: France Recent Past, Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 120: France Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 121: France 16-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2014, 2024 & 2030
  • TABLE 122: France Recent Past, Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 123: France Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 124: France 16-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 125: France Recent Past, Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 126: France Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 127: France 16-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2014, 2024 & 2030
• GERMANY
  • Pharmacovigilance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 128: Germany Recent Past, Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 129: Germany Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 130: Germany 16-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2014, 2024 & 2030
  • TABLE 131: Germany Recent Past, Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 132: Germany Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 133: Germany 16-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2014, 2024 & 2030
  • TABLE 134: Germany Recent Past, Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 135: Germany Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 136: Germany 16-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 137: Germany Recent Past, Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 138: Germany Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 139: Germany 16-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 140: Italy Recent Past, Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 141: Italy Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 142: Italy 16-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2014, 2024 & 2030
  • TABLE 143: Italy Recent Past, Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 144: Italy Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 145: Italy 16-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2014, 2024 & 2030
  • TABLE 146: Italy Recent Past, Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 147: Italy Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 148: Italy 16-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 149: Italy Recent Past, Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 150: Italy Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 151: Italy 16-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Pharmacovigilance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 152: UK Recent Past, Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 153: UK Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 154: UK 16-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2014, 2024 & 2030
  • TABLE 155: UK Recent Past, Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 156: UK Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 157: UK 16-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2014, 2024 & 2030
  • TABLE 158: UK Recent Past, Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 159: UK Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 160: UK 16-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 161: UK Recent Past, Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 162: UK Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 163: UK 16-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 164: Spain Recent Past, Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 165: Spain Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 166: Spain 16-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2014, 2024 & 2030
  • TABLE 167: Spain Recent Past, Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 168: Spain Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 169: Spain 16-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2014, 2024 & 2030
  • TABLE 170: Spain Recent Past, Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 171: Spain Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 172: Spain 16-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 173: Spain Recent Past, Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 174: Spain Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 175: Spain 16-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 176: Russia Recent Past, Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 177: Russia Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 178: Russia 16-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2014, 2024 & 2030
  • TABLE 179: Russia Recent Past, Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 180: Russia Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 181: Russia 16-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2014, 2024 & 2030
  • TABLE 182: Russia Recent Past, Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 183: Russia Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 184: Russia 16-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 185: Russia Recent Past, Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 186: Russia Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 187: Russia 16-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 189: Rest of Europe Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 190: Rest of Europe 16-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2014, 2024 & 2030
  • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 192: Rest of Europe Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 193: Rest of Europe 16-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2014, 2024 & 2030
  • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 195: Rest of Europe Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 196: Rest of Europe 16-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 198: Rest of Europe Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 199: Rest of Europe 16-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Pharmacovigilance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Pharmacovigilance by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Pharmacovigilance by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 202: Asia-Pacific 16-Year Perspective for Pharmacovigilance by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 205: Asia-Pacific 16-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2014, 2024 & 2030
  • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 207: Asia-Pacific Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 208: Asia-Pacific 16-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2014, 2024 & 2030
  • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 210: Asia-Pacific Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 211: Asia-Pacific 16-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 213: Asia-Pacific Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 214: Asia-Pacific 16-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2014, 2024 & 2030
• AUSTRALIA
  • Pharmacovigilance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 215: Australia Recent Past, Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 216: Australia Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 217: Australia 16-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2014, 2024 & 2030
  • TABLE 218: Australia Recent Past, Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 219: Australia Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 220: Australia 16-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2014, 2024 & 2030
  • TABLE 221: Australia Recent Past, Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 222: Australia Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 223: Australia 16-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 224: Australia Recent Past, Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 225: Australia Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 226: Australia 16-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2014, 2024 & 2030
• INDIA
  • Pharmacovigilance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 227: India Recent Past, Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 228: India Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 229: India 16-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2014, 2024 & 2030
  • TABLE 230: India Recent Past, Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 231: India Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 232: India 16-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2014, 2024 & 2030
  • TABLE 233: India Recent Past, Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 234: India Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 235: India 16-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 236: India Recent Past, Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 237: India Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 238: India 16-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 239: South Korea Recent Past, Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 240: South Korea Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 241: South Korea 16-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2014, 2024 & 2030
  • TABLE 242: South Korea Recent Past, Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 243: South Korea Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 244: South Korea 16-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2014, 2024 & 2030
  • TABLE 245: South Korea Recent Past, Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 246: South Korea Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 247: South Korea 16-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 248: South Korea Recent Past, Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 249: South Korea Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 250: South Korea 16-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 252: Rest of Asia-Pacific Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 253: Rest of Asia-Pacific 16-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2014, 2024 & 2030
  • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 255: Rest of Asia-Pacific Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 256: Rest of Asia-Pacific 16-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2014, 2024 & 2030
  • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 258: Rest of Asia-Pacific Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 259: Rest of Asia-Pacific 16-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 261: Rest of Asia-Pacific Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 262: Rest of Asia-Pacific 16-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • Pharmacovigilance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Pharmacovigilance by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Pharmacovigilance by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 265: Latin America 16-Year Perspective for Pharmacovigilance by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 268: Latin America 16-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2014, 2024 & 2030
  • TABLE 269: Latin America Recent Past, Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 270: Latin America Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 271: Latin America 16-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2014, 2024 & 2030
  • TABLE 272: Latin America Recent Past, Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 273: Latin America Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 274: Latin America 16-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 275: Latin America Recent Past, Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 276: Latin America Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 277: Latin America 16-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 278: Argentina Recent Past, Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 279: Argentina Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 280: Argentina 16-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2014, 2024 & 2030
  • TABLE 281: Argentina Recent Past, Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 282: Argentina Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 283: Argentina 16-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2014, 2024 & 2030
  • TABLE 284: Argentina Recent Past, Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 285: Argentina Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 286: Argentina 16-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 287: Argentina Recent Past, Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 288: Argentina Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 289: Argentina 16-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 290: Brazil Recent Past, Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 291: Brazil Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 292: Brazil 16-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2014, 2024 & 2030
  • TABLE 293: Brazil Recent Past, Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 294: Brazil Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 295: Brazil 16-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2014, 2024 & 2030
  • TABLE 296: Brazil Recent Past, Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 297: Brazil Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 298: Brazil 16-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 299: Brazil Recent Past, Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 300: Brazil Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 301: Brazil 16-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 302: Mexico Recent Past, Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 303: Mexico Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 304: Mexico 16-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2014, 2024 & 2030
  • TABLE 305: Mexico Recent Past, Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 306: Mexico Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 307: Mexico 16-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2014, 2024 & 2030
  • TABLE 308: Mexico Recent Past, Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 309: Mexico Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 310: Mexico 16-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 311: Mexico Recent Past, Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 312: Mexico Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 313: Mexico 16-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 315: Rest of Latin America Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 316: Rest of Latin America 16-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2014, 2024 & 2030
  • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 318: Rest of Latin America Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 319: Rest of Latin America 16-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2014, 2024 & 2030
  • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 321: Rest of Latin America Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 322: Rest of Latin America 16-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 324: Rest of Latin America Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 325: Rest of Latin America 16-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • Pharmacovigilance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Pharmacovigilance by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Pharmacovigilance by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 328: Middle East 16-Year Perspective for Pharmacovigilance by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 331: Middle East 16-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2014, 2024 & 2030
  • TABLE 332: Middle East Recent Past, Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 333: Middle East Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 334: Middle East 16-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2014, 2024 & 2030
  • TABLE 335: Middle East Recent Past, Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 336: Middle East Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 337: Middle East 16-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 338: Middle East Recent Past, Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 339: Middle East Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 340: Middle East 16-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 341: Iran Recent Past, Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 342: Iran Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 343: Iran 16-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2014, 2024 & 2030
  • TABLE 344: Iran Recent Past, Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 345: Iran Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 346: Iran 16-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2014, 2024 & 2030
  • TABLE 347: Iran Recent Past, Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 348: Iran Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 349: Iran 16-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 350: Iran Recent Past, Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 351: Iran Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 352: Iran 16-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 353: Israel Recent Past, Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 354: Israel Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 355: Israel 16-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2014, 2024 & 2030
  • TABLE 356: Israel Recent Past, Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 357: Israel Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 358: Israel 16-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2014, 2024 & 2030
  • TABLE 359: Israel Recent Past, Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 360: Israel Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 361: Israel 16-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 362: Israel Recent Past, Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 363: Israel Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 364: Israel 16-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 366: Saudi Arabia Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 367: Saudi Arabia 16-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2014, 2024 & 2030
  • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 369: Saudi Arabia Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 370: Saudi Arabia 16-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2014, 2024 & 2030
  • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 372: Saudi Arabia Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 373: Saudi Arabia 16-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 375: Saudi Arabia Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 376: Saudi Arabia 16-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 377: UAE Recent Past, Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 378: UAE Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 379: UAE 16-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2014, 2024 & 2030
  • TABLE 380: UAE Recent Past, Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 381: UAE Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 382: UAE 16-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2014, 2024 & 2030
  • TABLE 383: UAE Recent Past, Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 384: UAE Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 385: UAE 16-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 386: UAE Recent Past, Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 387: UAE Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 388: UAE 16-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 390: Rest of Middle East Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 391: Rest of Middle East 16-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2014, 2024 & 2030
  • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 393: Rest of Middle East Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 394: Rest of Middle East 16-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2014, 2024 & 2030
  • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 396: Rest of Middle East Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 397: Rest of Middle East 16-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 399: Rest of Middle East Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 400: Rest of Middle East 16-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2014, 2024 & 2030
• AFRICA
  • Pharmacovigilance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 401: Africa Recent Past, Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 402: Africa Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 403: Africa 16-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2014, 2024 & 2030
  • TABLE 404: Africa Recent Past, Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 405: Africa Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 406: Africa 16-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2014, 2024 & 2030
  • TABLE 407: Africa Recent Past, Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 408: Africa Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 409: Africa 16-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 410: Africa Recent Past, Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 411: Africa Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 412: Africa 16-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2014, 2024 & 2030

IV. COMPETITION